Michael Pulley, MD
Neurology · Jacksonville, FLNPI 1851360887
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $76,061 of the $116,838 with a category attached, or 65.1%. 24 manufacturers reported payments, led by AstraZeneca at 31.8% of the total. Reporting peaked in 2024 at $26,568 and has fallen 72.9% since, to $7,187 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $912.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$37K
- CSL Behring$26K
- Catalyst Pharmaceuticals, Inc.$9K
- Johnson & Johnson$8K
- UCB, Inc.$7K
- Grifols USA, LLC$6K
- plus $23K from 18 others
Across 140 payments — averaging $3264.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$163K
- Argenx US, Inc.$102K
- UCB SA$38K
- Ares Trading SA$37K
- Orion Corporation$35K
- Tanabe Pharma America, Inc.$27K
- plus $56K from 5 others
What the payments were for
- Consulting fees$76,06165%
- Speaking & faculty fees$30,90126%
- Travel & lodging$7,5426%
- Food & beverage$2,2592%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $37,142 |
| CSL Behring | 32 | $26,269 |
| Catalyst Pharmaceuticals, Inc. | 14 | $9,286 |
| Johnson & Johnson(2 entities) | 6 | $8,189 |
| UCB, Inc. | 4 | $7,016 |
| Grifols USA, LLC | 6 | $5,614 |
| Amgen | 2 | $3,119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $2,974 |
| Bio Products Laboratory USA, Inc. | 2 | $2,750 |
| Amylyx Pharmaceuticals, Inc. | 2 | $2,656 |
| F. Hoffmann-la Roche AG | 4 | $2,415 |
| Janssen Scientific Affairs, LLC | 1 | $2,031 |
| Vertex | 5 | $1,883 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,200 |
| Argenx US, Inc. | 1 | $1,150 |
| Tanabe Pharma America, Inc. | 3 | $1,108 |
| AbbVie | 2 | $600 |
| Samsung Bioepis Co., Ltd. | 1 | $550 |
| ITF Therapeutics LLC | 1 | $385 |
| Biocryst Pharmaceuticals, Inc. | 1 | $290 |
| Dr.reddy's Laboratories,inc. | 1 | $147 |
| EMD Serono, Inc. | 1 | $29 |
| EDW Pharma, Inc. | 1 | $24 |
| Biogen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,838 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 38 | $2,338,145 |
| Radicava OrsEdaravone | 119 | $1,708,932 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 23 | $1,408,916 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 57 | $821,792 |
| VyvgartEfgartigimod Alfa-Fcab | 20 | $756,827 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $524,359 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 17 | $394,002 |
| EvrysdiRisdiplam | 11 | $293,981 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $196,805 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 11 | $152,085 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 48 | $103,969 |
| NuedextaDextromethorphan Hbr/Quinidine | 27 | $53,094 |
| Mycophenolate Mofetil | 153 | $50,249 |
| Riluzole | 94 | $10,120 |
| Pyridostigmine Bromide | 104 | $8,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris | $37,142 | $2,338,14538 claims |
| Argenx US, Inc.Vyvgart Hytrulo, Vyvgart | $1,150 | $2,165,74443 claims |
| CSL BehringPrivigen, Hizentra | $26,269 | $1,346,15172 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $2,974 | $196,80526 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $2,656 | $152,08511 claims |
| Grifols USA, LLCGamunex-C | $5,614 | $103,96948 claims |
| Dr.reddy's Laboratories,inc.Pregabalin | $147 | $1,11136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Jacksonville
- Steven ToenjesJacksonville$695K
- Zhigao HuangJacksonville$613K
- Kalina SandersJacksonville$544K
- Syed AsadJacksonville$302K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.